Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: According to global data, hernia surgery is the most commonly performed elective surgical procedure. The primary factor that can lead to the development of a hernia is weakening of the abdominal wall. The only effective method of treating hernias, regardless of their type, is surgery. In the following clinical study, a retrospective - prospective analysis was performed. The aim of the study was to determine, based on open and laparoscopic techniques, the effectiveness and safety of Optomesh ULTRALIGHT surgical meshes made from cuts of stabilized monofilament polypropylene knit fabric recommended for reconstructive surgical procedures to fill and/or strengthen soft tissue defects in the treatment of various types of hernias.
Methods: The study included 171 patients, aged 22 to 70 years, who met the inclusion and exclusion criteria specified in the clinical trial plan, including 20 women and 151 men. During surgery, the vast majority of hernias were operated using the Lichtenstein surgical technique (132 patients). The other operations were performed using the Rives-Stoppa technique (23) and laparoscopic TAPP, TEP technique (16).
Results: The results were collected from intraoperative data and data collected during 2 follow-up visits after the procedure. The presented data collected during interviews with patients concern the frequency of recurrences, pain sensation in the first days after the procedure, discomfort associated with mesh implantation and pain sensation according to the VAS scale. These parameters will help to assess the therapeutic value of this type of implants intended for surgical treatment of hernias. Interviews at the second follow-up visit confirmed the patients' long-term, satisfactory reception in terms of comfort and average pain sensation.
Conclusions: The Optomesh ULTRALIGHT implant is not only effective and safe but also imperceptible to the patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204886 | PMC |
| http://dx.doi.org/10.1007/s10029-025-03398-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-world study on the safety and efficacy of therapeutic plasma exchange in patients with Alzheimer's disease.
J Alzheimers Dis
September 2025
Paula Costa-Urrutia Medical Affairs, Terumo BCT, Edificio Think MVD, Montevideo, Uruguay.
BackgroundTherapeutic plasma exchange (TPE) with albumin replacement has emerged as a potential treatment for Alzheimer's disease (AD). The AMBAR trial showed that TPE could slow cognitive and functional decline, along with changes in core and inflammatory biomarkers in cerebrospinal fluid.ObjectiveTo evaluate the safety and effectiveness of TPE in a real-world setting in Argentina.
View Article and Find Full Text PDFApproach to the Postmarket Evaluation of Consumer Wearable Technologies.
JAMA Cardiol
September 2025
Department of Medicine, Cardiovascular Medicine, Stanford University, Stanford, California.
Importance: Consumer wearable technologies have wide applications, including some that have US Food and Drug Administration clearance for health-related notifications. While wearable technologies may have premarket testing, validation, and safety evaluation as part of a regulatory authorization process, information on their postmarket use remains limited. The Stanford Center for Digital Health organized 2 pan-stakeholder think tank meetings to develop an organizing concept for empirical research on the postmarket evaluation of consumer-facing wearables.
View Article and Find Full Text PDFComparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.
JAMA Netw Open
September 2025
Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla.
Importance: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.
Objective: To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.
Oral immunotherapy in children with allergic diseases: past, present and future.
Minerva Pediatr (Torino)
September 2025
Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.
Allergen immunotherapy (AIT) is the only treatment capable of modifying the natural history of allergic diseases by promoting immune tolerance. Initially developed for respiratory allergies, AIT has expanded to include food allergies, particularly through oral immunotherapy (OIT). This review explores the historical evolution, current applications, and future directions of AIT in pediatric patients.
View Article and Find Full Text PDFFrom neglected to notoriety: a review of Mpox clinical features, virology, epidemiology, treatment and prevention strategies.
Eur J Clin Microbiol Infect Dis
September 2025
Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France.
Purpose: This narrative review aims to provide an overview of current knowledge on mpox, emphasizing updated epidemiology and recent advances in treatment and prevention strategies, in light of the latest outbreaks.
Methods: We searched PubMed and Google Scholar for publications on 'Mpox' and 'Monkeypox' up to June 5, 2025. Grey literature from governmental and health agencies was also accessed for outbreak reports and guidelines where published evidence was unavailable.